E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
With the unit classified as VAI, Aurobindo Pharma said pending applications for multiple inhalers and other dosage forms filed from the facility can now progress through the USFDA’s review process.
imphoenix82
Aurobindo Pharma said the warning letter to Unit I of Eugia Pharma Specialities will have no impact on existing supplies to the US market.
imphoenix82
CuraTeQ Biologics Private Ltd., a wholly owned subsidiary of Aurobindo Pharma Ltd., has received Good Manufacturing Practice (GMP) approval from Brazil’s National Health Surveillance Agency (ANVISA) for its biosimilars manufacturing facility in Hyderabad. According to a stock exchange filing, ANVISA conducted a GMP inspection of the facility from May 11 to May 15, 2026. The […]
imphoenix82
The transfer was executed on a slump sale basis in accordance with the Business Transfer Agreement (BTA) signed between Aurobindo Pharma and Auropharm.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
